Alpha Tau Medical Ltd (DRTS) - Net Assets
Based on the latest financial reports, Alpha Tau Medical Ltd (DRTS) has net assets worth $77.58 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($104.69 Million) and total liabilities ($27.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Alpha Tau Medical Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $77.58 Million |
| % of Total Assets | 74.11% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2.88 |
Alpha Tau Medical Ltd - Net Assets Trend (2019–2024)
This chart illustrates how Alpha Tau Medical Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of Alpha Tau Medical Ltd.
Annual Net Assets for Alpha Tau Medical Ltd (2019–2024)
The table below shows the annual net assets of Alpha Tau Medical Ltd from 2019 to 2024. Also explore Alpha Tau Medical Ltd (DRTS) equity growth momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $62.67 Million | -25.82% |
| 2023-12-31 | $84.47 Million | -20.05% |
| 2022-12-31 | $105.66 Million | +403.81% |
| 2021-12-31 | $-34.78 Million | -312.59% |
| 2020-12-31 | $-8.43 Million | -4267.36% |
| 2019-12-31 | $-193.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alpha Tau Medical Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13082200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $210.18 Million | 335.39% |
| Total Equity | $62.67 Million | 100.00% |
Alpha Tau Medical Ltd Competitors by Market Cap
The table below lists competitors of Alpha Tau Medical Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Svolder AB (publ)
ST:SVOL-B
|
$614.87 Million |
|
Grid Dynamics Holdings Inc
NASDAQ:GDYN
|
$614.94 Million |
|
Shenzhen Guangju Energy Co Ltd
SHE:000096
|
$615.01 Million |
|
Waga Energy SA
PA:WAGA
|
$615.05 Million |
|
India Tourism Development Corporation Limited
NSE:ITDC
|
$614.70 Million |
|
SurModics Inc
NASDAQ:SRDX
|
$614.51 Million |
|
CytomX Therapeutics Inc
NASDAQ:CTMX
|
$614.48 Million |
|
MarineMax Inc
NYSE:HZO
|
$614.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alpha Tau Medical Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 84,475,000 to 62,666,000, a change of -21,809,000 (-25.8%).
- Net loss of 31,750,000 reduced equity.
- Other factors increased equity by 9,941,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-31.75 Million | -50.67% |
| Other Changes | $9.94 Million | +15.86% |
| Total Change | $- | -25.82% |
Book Value vs Market Value Analysis
This analysis compares Alpha Tau Medical Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 17.28x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.00 | $15.49 | x |
| 2020-12-31 | $-0.21 | $15.49 | x |
| 2021-12-31 | $-0.86 | $15.49 | x |
| 2022-12-31 | $1.66 | $15.49 | x |
| 2023-12-31 | $1.22 | $15.49 | x |
| 2024-12-31 | $0.90 | $15.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alpha Tau Medical Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -50.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.38x
- Recent ROE (-50.67%) is below the historical average (-19.52%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.44 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.04 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.79 Million |
| 2022 | -31.95% | 0.00% | 0.00x | 1.14x | $-44.33 Million |
| 2023 | -34.52% | 0.00% | 0.00x | 1.27x | $-37.60 Million |
| 2024 | -50.67% | 0.00% | 0.00x | 1.38x | $-38.02 Million |
Industry Comparison
This section compares Alpha Tau Medical Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alpha Tau Medical Ltd (DRTS) | $77.58 Million | 0.00% | 0.35x | $614.75 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending cl… Read more